Zacks Investment Research on MSN1d
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Vertex non-opioid painkiller Journavx gets mixed ICER review
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Pharmaceutical Technology on MSN2d
Vertex halts development of diabetes cell therapy after trial failure
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.